oral CAT K inhibitior
reduced uCTX-I levels in dog model
from opt of a previously disclosed cmpd
Bioorg. Med. Chem. Lett.
Merck, West Point, PA
Context. “Compound 23” (Merck) is a selective oral cathepsin K (CatK) inhibitor intended for osteoarthritis. Osteoarthritis affects around 15% of the population, and current treatments offer only symptom relief,…